Clinical Endocrinology, Volume 103, Issue 1, Page 21-35, July 2025.ABSTRACT Objective Managing gastrointestinal symptoms in patients with phaeochromocytoma and paraganglioma (PPGL) is challenging due to the risk of catecholaminergic crisis with many commonly prescribed medications, especially in functional tumours.
Monica Majumder +5 more
wiley +1 more source
Asian Journal of Medical SciencesBackground: Spinal anesthesia is the most common regional anesthesia used to provide surgical anesthesia for cesarean section. Nausea and vomiting are common symptoms experienced by patients undergoing cesarean section. Aims and Objectives: The aim of
Vankudoth Bhaskar +3 more
doaj +1 more source
RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE [PDF]
, 2012 Background: Scientific data provide today the evidence that secondary K-RAS mutations do not occur during anti-EGFR therapy in CRC patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab ...
BRONTE, Giuseppe
core
Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39). [PDF]
, 2017 Preclinical studies show that the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin (9-39), can reduce acute emesis induced by cisplatin. In the present study, we investigate the effect of exendin (9-39) (100 nmol/24 h, i.c.v), on cisplatin (5
Aggarwal +74 more
core +1 more source
PLoS ONE, 2018 BackgroundThe preemptive multimodal pain protocols used in total knee arthroplasty (TKA) often cause emesis postoperatively. We investigated whether palonosetron prophylaxis reduces postoperative nausea and vomiting (PONV) in high-risk patients after TKA.
Jung-Hee Ryu +4 more
doaj +1 more source
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. [PDF]
, 2017 To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.
Daina, A., Michielin, O., Zoete, V.
core +1 more source
Internal Medicine Journal, Volume 55, Issue 5, Page 749-759, May 2025.Abstract Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline ...
Aditya Tedjaseputra +19 more
wiley +1 more source
Fatores de risco para náuseas e vômitos pós-operatórios no Hospital Universitário Polydoro Ernanni de São Thiago [PDF]
, 2012 Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Santos, Michele Caroline
core
Targets of drugs are generally, and targets of drugs having side effects are specifically good spreaders of human interactome perturbations [PDF]
, 2015 Network-based methods are playing an increasingly important role in drug design. Our main question in this paper was whether the efficiency of drug target proteins to spread perturbations in the human interactome is larger if the binding drugs have side ...
A Banerjee +53 more
core +4 more sources
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial [PDF]
, 2015 PURPOSE: Subcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0-24 h) and delayed (24-120 h) chemotherapy-induced nausea and vomiting (CINV).
Boccia, R. +5 more
core +2 more sources